Financhill
Sell
43

XNCR Quote, Financials, Valuation and Earnings

Last price:
$10.20
Seasonality move :
13.21%
Day range:
$10.47 - $11.14
52-week range:
$7.16 - $27.24
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.31x
P/B ratio:
1.11x
Volume:
1.2M
Avg. volume:
906.9K
1-year change:
-55.54%
Market cap:
$755.4M
Revenue:
$110.5M
EPS (TTM):
-$3.63

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
XNCR
Xencor
$24.8M -$0.58 46.51% -52.3% $30.30
AMGN
Amgen
$8B $4.26 5.6% 282.11% $313.62
CPRX
Catalyst Pharmaceuticals
$131.1M $0.53 14.53% 52.49% $34.00
PSTV
Plus Therapeutics
$1.1M -$0.29 -- -54.22% $9.83
RARE
Ultragenyx Pharmaceutical
$144.5M -$1.64 34.13% -20.2% $91.80
REGN
Regeneron Pharmaceuticals
$3.2B $8.48 -7.35% -30.58% $800.13
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
XNCR
Xencor
$10.72 $30.30 $755.4M -- $0.00 0% 6.31x
AMGN
Amgen
$280.06 $313.62 $150.6B 25.55x $2.38 3.26% 4.44x
CPRX
Catalyst Pharmaceuticals
$24.30 $34.00 $3B 18.55x $0.00 0% 6.17x
PSTV
Plus Therapeutics
$0.62 $9.83 $10.5M -- $0.00 0% 0.76x
RARE
Ultragenyx Pharmaceutical
$38.87 $91.80 $3.6B -- $0.00 0% 6.28x
REGN
Regeneron Pharmaceuticals
$603.58 $800.13 $65.2B 15.37x $0.88 0.15% 4.89x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
XNCR
Xencor
19.45% 2.752 10.16% 6.39x
AMGN
Amgen
90.24% 0.239 34.26% 0.74x
CPRX
Catalyst Pharmaceuticals
-- 0.175 -- 4.83x
PSTV
Plus Therapeutics
-- -0.140 -- --
RARE
Ultragenyx Pharmaceutical
-- 1.162 -- 2.13x
REGN
Regeneron Pharmaceuticals
6.33% 0.973 2.89% 3.90x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
XNCR
Xencor
-- -$13.2M -31.93% -35.99% -68.05% -$52.5M
AMGN
Amgen
$5.2B $1.2B 8.85% 97.08% 33.08% $980M
CPRX
Catalyst Pharmaceuticals
$120.2M $62.8M 27.81% 27.81% 44.31% $70.8M
PSTV
Plus Therapeutics
-- -$3.8M -- -- -- -$3.7M
RARE
Ultragenyx Pharmaceutical
$148M -$122.3M -194.36% -194.36% -71.5% -$80.2M
REGN
Regeneron Pharmaceuticals
$2.6B $591.7M 14.69% 15.7% 30.17% $773.6M

Xencor vs. Competitors

  • Which has Higher Returns XNCR or AMGN?

    Amgen has a net margin of -86.29% compared to Xencor's net margin of 21.23%. Xencor's return on equity of -35.99% beat Amgen's return on equity of 97.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.62 $837.6M
    AMGN
    Amgen
    63.58% $3.20 $63.6B
  • What do Analysts Say About XNCR or AMGN?

    Xencor has a consensus price target of $30.30, signalling upside risk potential of 182.65%. On the other hand Amgen has an analysts' consensus of $313.62 which suggests that it could grow by 11.98%. Given that Xencor has higher upside potential than Amgen, analysts believe Xencor is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    AMGN
    Amgen
    9 15 2
  • Is XNCR or AMGN More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Amgen has a beta of 0.502, suggesting its less volatile than the S&P 500 by 49.829%.

  • Which is a Better Dividend Stock XNCR or AMGN?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen offers a yield of 3.26% to investors and pays a quarterly dividend of $2.38 per share. Xencor pays -- of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or AMGN?

    Xencor quarterly revenues are $52.8M, which are smaller than Amgen quarterly revenues of $8.1B. Xencor's net income of -$45.6M is lower than Amgen's net income of $1.7B. Notably, Xencor's price-to-earnings ratio is -- while Amgen's PE ratio is 25.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 6.31x versus 4.44x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    6.31x -- $52.8M -$45.6M
    AMGN
    Amgen
    4.44x 25.55x $8.1B $1.7B
  • Which has Higher Returns XNCR or CPRX?

    Catalyst Pharmaceuticals has a net margin of -86.29% compared to Xencor's net margin of 39.44%. Xencor's return on equity of -35.99% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.62 $837.6M
    CPRX
    Catalyst Pharmaceuticals
    84.74% $0.44 $727.6M
  • What do Analysts Say About XNCR or CPRX?

    Xencor has a consensus price target of $30.30, signalling upside risk potential of 182.65%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $34.00 which suggests that it could grow by 39.92%. Given that Xencor has higher upside potential than Catalyst Pharmaceuticals, analysts believe Xencor is more attractive than Catalyst Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    CPRX
    Catalyst Pharmaceuticals
    7 0 0
  • Is XNCR or CPRX More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.697, suggesting its less volatile than the S&P 500 by 30.252%.

  • Which is a Better Dividend Stock XNCR or CPRX?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or CPRX?

    Xencor quarterly revenues are $52.8M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $141.8M. Xencor's net income of -$45.6M is lower than Catalyst Pharmaceuticals's net income of $55.9M. Notably, Xencor's price-to-earnings ratio is -- while Catalyst Pharmaceuticals's PE ratio is 18.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 6.31x versus 6.17x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    6.31x -- $52.8M -$45.6M
    CPRX
    Catalyst Pharmaceuticals
    6.17x 18.55x $141.8M $55.9M
  • Which has Higher Returns XNCR or PSTV?

    Plus Therapeutics has a net margin of -86.29% compared to Xencor's net margin of --. Xencor's return on equity of -35.99% beat Plus Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.62 $837.6M
    PSTV
    Plus Therapeutics
    -- -$0.37 --
  • What do Analysts Say About XNCR or PSTV?

    Xencor has a consensus price target of $30.30, signalling upside risk potential of 182.65%. On the other hand Plus Therapeutics has an analysts' consensus of $9.83 which suggests that it could grow by 1485.25%. Given that Plus Therapeutics has higher upside potential than Xencor, analysts believe Plus Therapeutics is more attractive than Xencor.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    PSTV
    Plus Therapeutics
    1 1 0
  • Is XNCR or PSTV More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.878, suggesting its less volatile than the S&P 500 by 12.185%.

  • Which is a Better Dividend Stock XNCR or PSTV?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or PSTV?

    Xencor quarterly revenues are $52.8M, which are larger than Plus Therapeutics quarterly revenues of --. Xencor's net income of -$45.6M is lower than Plus Therapeutics's net income of -$2.9M. Notably, Xencor's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 6.31x versus 0.76x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    6.31x -- $52.8M -$45.6M
    PSTV
    Plus Therapeutics
    0.76x -- -- -$2.9M
  • Which has Higher Returns XNCR or RARE?

    Ultragenyx Pharmaceutical has a net margin of -86.29% compared to Xencor's net margin of -80.9%. Xencor's return on equity of -35.99% beat Ultragenyx Pharmaceutical's return on equity of -194.36%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.62 $837.6M
    RARE
    Ultragenyx Pharmaceutical
    89.75% -$1.39 $262.3M
  • What do Analysts Say About XNCR or RARE?

    Xencor has a consensus price target of $30.30, signalling upside risk potential of 182.65%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $91.80 which suggests that it could grow by 136.17%. Given that Xencor has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Xencor is more attractive than Ultragenyx Pharmaceutical.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    RARE
    Ultragenyx Pharmaceutical
    12 1 0
  • Is XNCR or RARE More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.284%.

  • Which is a Better Dividend Stock XNCR or RARE?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Xencor pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or RARE?

    Xencor quarterly revenues are $52.8M, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $164.9M. Xencor's net income of -$45.6M is higher than Ultragenyx Pharmaceutical's net income of -$133.4M. Notably, Xencor's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 6.31x versus 6.28x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    6.31x -- $52.8M -$45.6M
    RARE
    Ultragenyx Pharmaceutical
    6.28x -- $164.9M -$133.4M
  • Which has Higher Returns XNCR or REGN?

    Regeneron Pharmaceuticals has a net margin of -86.29% compared to Xencor's net margin of 26.7%. Xencor's return on equity of -35.99% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    XNCR
    Xencor
    -- -$0.62 $837.6M
    REGN
    Regeneron Pharmaceuticals
    84.67% $7.27 $31.4B
  • What do Analysts Say About XNCR or REGN?

    Xencor has a consensus price target of $30.30, signalling upside risk potential of 182.65%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 32.56%. Given that Xencor has higher upside potential than Regeneron Pharmaceuticals, analysts believe Xencor is more attractive than Regeneron Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    XNCR
    Xencor
    8 0 0
    REGN
    Regeneron Pharmaceuticals
    13 5 0
  • Is XNCR or REGN More Risky?

    Xencor has a beta of 0.992, which suggesting that the stock is 0.85% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

  • Which is a Better Dividend Stock XNCR or REGN?

    Xencor has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.15% to investors and pays a quarterly dividend of $0.88 per share. Xencor pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XNCR or REGN?

    Xencor quarterly revenues are $52.8M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Xencor's net income of -$45.6M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Xencor's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 15.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Xencor is 6.31x versus 4.89x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XNCR
    Xencor
    6.31x -- $52.8M -$45.6M
    REGN
    Regeneron Pharmaceuticals
    4.89x 15.37x $3B $808.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Berkshire The Best Stock to Buy in a Bad Market?
Is Berkshire The Best Stock to Buy in a Bad Market?

Berkshire Hathaway (NYSE:BRK.A, BRK.B) has historically been one of the…

Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?
Is Shopify Stock Still a Buy in 2025 or Has Growth Peaked?

The big picture trends in e‑commerce sales are clearly in…

Is RTX The Best Growth Stock?
Is RTX The Best Growth Stock?

Among the worldwide aerospace and defense markets, the US controls…

Stock Ideas

Buy
71
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.8T
P/E Ratio: 39x

Alerts

Buy
60
RGC alert for May 6

Regencell Bioscience Holdings [RGC] is up 86.55% over the past day.

Buy
63
SKX alert for May 6

Skechers USA [SKX] is down 0.02% over the past day.

Sell
20
PTCT alert for May 6

PTC Therapeutics [PTCT] is down 2.73% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock